AR058605A1 - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
AR058605A1
AR058605A1 ARP060105709A ARP060105709A AR058605A1 AR 058605 A1 AR058605 A1 AR 058605A1 AR P060105709 A ARP060105709 A AR P060105709A AR P060105709 A ARP060105709 A AR P060105709A AR 058605 A1 AR058605 A1 AR 058605A1
Authority
AR
Argentina
Prior art keywords
insulin sensitizer
solid preparation
active ingredient
insulin
sensitizer
Prior art date
Application number
ARP060105709A
Other languages
English (en)
Inventor
K Kiyoshima
K Nakamura
T Kawano
M Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR058605A1 publication Critical patent/AR058605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente pretende proporcionar una preparacion solida que contiene un sensibilizante de insulina como por ejemplo pioglitazona, entre otros y un ingrediente activo distinto de un sensibilizante de insulina, como por ejemplo un secretagogo de insulina, y exhibe comportamiento de disolucion de un sensibilizante de insulina similar al de un sensibilizante de insulina proveniente de ôuna preparacion solida que solo contiene un sensibilizante de insulina como ingrediente activoö. La preparacion solida comprende ôuna parte que contiene partículas recubiertas en donde las partículas que contienen un sensibilizante de insulina están recubiertas con lactosa o un azucar alcoholö y ôuna parte que contiene un ingrediente activo distinto de un sensibilizante de insulina.
ARP060105709A 2005-12-22 2006-12-21 Preparacion solida AR058605A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005370375 2005-12-22

Publications (1)

Publication Number Publication Date
AR058605A1 true AR058605A1 (es) 2008-02-13

Family

ID=37951491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105709A AR058605A1 (es) 2005-12-22 2006-12-21 Preparacion solida

Country Status (24)

Country Link
US (1) US8071130B2 (es)
EP (1) EP1962811B1 (es)
JP (1) JP5179363B2 (es)
KR (1) KR20080080126A (es)
CN (1) CN101384251B (es)
AR (1) AR058605A1 (es)
AU (1) AU2006328328B2 (es)
BR (1) BRPI0620020A2 (es)
CA (1) CA2633149C (es)
CR (1) CR10032A (es)
ES (1) ES2576258T3 (es)
GE (1) GEP20115245B (es)
HR (1) HRP20160679T1 (es)
IL (1) IL191774A0 (es)
MA (1) MA30061B1 (es)
MY (1) MY149306A (es)
NO (1) NO20083104L (es)
NZ (1) NZ569071A (es)
PE (1) PE20110019A1 (es)
RU (1) RU2426530C2 (es)
TW (1) TWI384985B (es)
UA (1) UA91729C2 (es)
WO (1) WO2007072992A2 (es)
ZA (1) ZA200805147B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534374T1 (de) 2006-05-23 2011-12-15 Takeda Pharmaceutical Orale zubereitung mit pioglitazon
UA95828C2 (ru) 2007-02-01 2011-09-12 Такеда Фармасьютикал Компани Лимитед Твердая рецептура, которая содержит алоглиптин и пиоглитазон
EP2184056B1 (en) * 2007-08-27 2019-04-24 Asahi Kasei Kabushiki Kaisha Process for production of tablets containing both crystalline cellulose and granules
WO2010085014A1 (en) * 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SG10201407947WA (en) * 2009-11-30 2015-01-29 Aptalis Pharmatech Inc Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
CN101804056A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 盐酸吡格列酮、格列美脲的复方片剂及制备方法
JP2013538807A (ja) 2010-09-01 2013-10-17 ルピン・リミテッド メトホルミンおよびピオグリタゾンを含む医薬組成物
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
FR2966828B1 (fr) * 2010-11-02 2012-12-28 Roquette Freres Poudre de polysaccharide et de polyol, comprimable et de haute viscosite
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
WO2013034436A1 (de) * 2011-09-08 2013-03-14 Hexal Ag Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin
EA201490840A1 (ru) 2011-10-21 2014-08-29 Такеда Фармасьютикал Компани Лимитед Препарат с замедленным высвобождением
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN102641280A (zh) * 2012-04-23 2012-08-22 重庆康刻尔制药有限公司 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
KR101782119B1 (ko) * 2016-02-01 2017-10-23 주식회사 한독 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
CN111410687B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种长效glp-1化合物
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3152978B2 (ja) 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
UA67743C2 (uk) 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1561458B1 (en) * 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
AU768994B2 (en) * 1998-11-12 2004-01-15 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
RU2177318C1 (ru) 2000-12-21 2001-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидиабетическим действием и способ ее получения
US20040147584A2 (en) * 2001-12-05 2004-07-29 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20060286168A1 (en) * 2002-07-11 2006-12-21 Masahiko Koike Process for producing coated preparation
BR0306208A (pt) * 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
WO2004069229A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof
WO2004091587A1 (en) 2003-04-17 2004-10-28 Ipca Laboratories Limited Multiple release anti-diabetic drugs and process of production thereof
BRPI0410555A (pt) 2003-06-06 2006-06-20 Takeda Pharmaceutical preparação sólida
NZ544307A (en) * 2003-06-27 2008-12-24 Reddy Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
EP1738754B1 (en) * 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2005102290A1 (en) 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Pharmaceutical compositions of a biguanide and a sulfonylurea

Also Published As

Publication number Publication date
HRP20160679T1 (hr) 2016-07-15
IL191774A0 (en) 2008-12-29
CA2633149C (en) 2015-06-30
BRPI0620020A2 (pt) 2011-10-25
TWI384985B (zh) 2013-02-11
NZ569071A (en) 2011-01-28
WO2007072992A3 (en) 2007-12-06
AU2006328328B2 (en) 2012-08-30
CN101384251A (zh) 2009-03-11
CN101384251B (zh) 2014-09-03
AU2006328328A1 (en) 2007-06-28
NO20083104L (no) 2008-09-19
UA91729C2 (ru) 2010-08-25
MA30061B1 (fr) 2008-12-01
US20090028939A1 (en) 2009-01-29
KR20080080126A (ko) 2008-09-02
CR10032A (es) 2008-10-03
US8071130B2 (en) 2011-12-06
RU2426530C2 (ru) 2011-08-20
GEP20115245B (en) 2011-06-27
MY149306A (en) 2013-08-30
EP1962811B1 (en) 2016-04-27
JP2009520681A (ja) 2009-05-28
PE20110019A1 (es) 2011-01-27
WO2007072992A2 (en) 2007-06-28
RU2008130074A (ru) 2010-01-27
ES2576258T3 (es) 2016-07-06
TW200731971A (en) 2007-09-01
JP5179363B2 (ja) 2013-04-10
EP1962811A2 (en) 2008-09-03
CA2633149A1 (en) 2007-06-28
ZA200805147B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
AR058605A1 (es) Preparacion solida
EG25341A (en) Combinations of pesticidal active substance combinations.
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CR8713A (es) Mezclas de pesticidas
CR20110110A (es) Composicion farmaceutica
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
ZA200709169B (en) Combinations of pesticidal active substance combinations
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2008019871A3 (de) Neue salze des wirkstoffs rasagilin
WO2007074454A3 (en) Stable enzymatic preparations and methods of use thereof
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2009066146A3 (en) Stable solutions of sparingly soluble actives
BRPI0620229A8 (pt) formulação
CO6311067A2 (es) Preparación de comprimido con liberación retardada que contiene polivinilpirrolidonas y principio activo
WO2007019272A8 (en) Method for time based event structure and compliance
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
DK1838315T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til fremstilling heraf, deres anvendelse som medikament samt medikamenter indeholdende dem
MY165041A (en) Composition for improving brain function and method for improving brain function
TW200640724A (en) Display for a vehicle
UY31452A1 (es) Recubrimiento mejorado de tableta
CR9523A (es) Tableta recubierta de azucar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal